palbociclib

Open Access
Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models
ISMAHENE BENZAID, MARC HILLAIRET DE BOISFERON, ELODIE MARIE DIT CHATEL and BRUCE A. LITTLEFIELD

Anticancer Research January 2024, 44 (1) 61-70; DOI: https://doi.org/10.21873/anticanres.16788
Open Access
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies
CHUN-MING CHANG and HO YIN PEKKLE LAM

Anticancer Research December 2023, 43 (12) 5283-5298; DOI: https://doi.org/10.21873/anticanres.16732
You have access
Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
MIDORI MORITA, ASAKO OOE, WATARU ISHII, AKIRA WATANABE, CHISE MATSUI, YUKA OKUYAMA, SAE KITANO, CHIKAGE KATO, MIE ONISHI, KOICHI SAKAGUCHI and YASUTO NAOI

Anticancer Research June 2023, 43 (6) 2783-2789; DOI: https://doi.org/10.21873/anticanres.16447
You have access
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer
HIROHITO SEKI, TAKASHI SAKURAI, AKIHISA SAKURADA, TETSUHIKO KINOSHITA and KEN SHIMIZU

Anticancer Research February 2022, 42 (2) 1099-1106; DOI: https://doi.org/10.21873/anticanres.15572
You have access
Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
HIROMICHI OSHIRO, YASUNORI TOME, KENTARO MIYAKE, TAKASHI HIGUCHI, NORIHIKO SUGISAWA, FUMINORI KANAYA, KOTARO NISHIDA and ROBERT M. HOFFMAN

Anticancer Research July 2021, 41 (7) 3287-3292; DOI: https://doi.org/10.21873/anticanres.15115
You have access
Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy
UMAIR M. NASIR, ALEXANDER M. MOZEIKA, MUTLAY SAYAN, IMRAAN JAN, NOEL KOWAL, BRUCE HAFFTY, SUSHIL AHLAWAT and NEIL KOTHARI

Anticancer Research September 2020, 40 (9) 5291-5294; DOI: https://doi.org/10.21873/anticanres.14534
You have access
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model
TAKASHI HIGUCHI, NORIHIKO SUGISAWA, KENTARO MIYAKE, HIROMICHI OSHIRO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, SANT P. CHAWLA, MICHAEL BOUVET, SHREE RAM SINGH, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN

Anticancer Research August 2019, 39 (8) 4079-4084; DOI: https://doi.org/10.21873/anticanres.13565
You have access
PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and Molecular Markers Predict for Sensitivity
JOSHUA E. LOGAN, NIKAYEH MOSTOFIZADEH, AMRITA J. DESAI, ERIKA VON EUW, DYLAN CONKLIN, VEERAUO KONKANKIT, HABIB HAMIDI, MARK ECKARDT, LEE ANDERSON, HSIAO-WANG CHEN, CHARLES GINTHER, EILEEN TASCHEREAU, PETER H. BUI, JAMES G. CHRISTENSEN, ARIE S. BELLDEGRUN, DENNIS J. SLAMON and FAIROOZ F. KABBINAVAR

Anticancer Research August 2013, 33 (8) 2997-3004;

Main menu

User menu

Search

palbociclib